CLINICAL RESEARCH: HEART FAILURE
Natriuretic Peptides Enhance the Production of Adiponectin in Human Adipocytes and in Patients With Chronic Heart Failure
Osamu Tsukamoto, MD, PhD*, ,
Masashi Fujita, MD, PhD,
Mahoto Kato, MD*,
Satoru Yamazaki, PhD*,
Yoshihiro Asano, MD, PhD,
Akiko Ogai, PhD*,
Hidetoshi Okazaki, MD, PhD*,
Mitsutoshi Asai, MD,
Yoko Nagamachi, BS,
Norikazu Maeda, MD, PhD ,
Yasunori Shintani, MD, PhD,
Tetsuo Minamino, MD, PhD,
Masanori Asakura, MD, PhD*,
Ichiro Kishimoto, MD, PhD ,
Tohru Funahashi, MD, PhD,
Hitonobu Tomoike, MD, PhD* and
Masafumi Kitakaze, MD, PhD*,*
* Cardiovascular Division of Medicine, National Cardiovascular Center, Suita, Osaka, Japan
Cardiovasular Division of Biochemistry, National Cardiovascular Center, Suita, Osaka, Japan
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Manuscript received August 27, 2008;
revised manuscript received January 22, 2009,
accepted February 19, 2009.
* Reprint requests and correspondence: Dr. Masafumi Kitakaze, Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka 565-8565, Japan (Email: kitakaze{at}zf6.so-net.ne.jp).
Objectives: We investigated the functional relationship between natriuretic peptides and adiponectin by performing both experimental and clinical studies.
Background: Natriuretic peptides are promising candidates for the treatment of congestive heart failure (CHF) because of their wide range of beneficial effects on the cardiovascular system. Adiponectin is a cytokine derived from adipose tissue with various cardiovascular-protective effects that has been reported to show a positive association with plasma brain natriuretic peptide (BNP) levels in patients with heart failure.
Methods: The expression of adiponectin messenger ribonucleic acid (mRNA) and its secretion were examined after atrial natriuretic peptide (ANP) or BNP was added to primary cultures of human adipocytes in the presence or absence of HS142-1 (a functional type A guanylyl cyclase receptor antagonist). Changes of the plasma adiponectin level were determined in 30 patients with CHF who were randomized to receive intravenous ANP (0.025 µg/kg/min human ANP for 3 days, n = 15) or saline (n = 15).
Results: Both ANP and BNP dose-dependently enhanced the expression of adiponectin mRNA and its secretion, whereas such enhancement was inhibited by pre-treatment with HS142-1. The plasma adiponectin level was increased at 4 days after administration of human ANP compared with the baseline value (from 6.56 ± 0.40 µg/ml to 7.34 ± 0.47 µg/ml, p < 0.05), whereas there was no change of adiponectin in the saline group (from 6.53 ± 0.57 µg/ml to 6.55 ± 0.56 µg/ml).
Conclusions: Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF, which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy for heart failure.
Key Words: adiponectin • natriuretic peptides • heart failure • adipose tissue
|
Abbreviations and Acronyms
| | ANP = atrial natriuretic peptide | | BNP = brain natriuretic peptide | | CHF = congestive heart failure | | GC-A = type A guanylyl cyclase receptor | | hANP = human atrial natriuretic peptide | | NPR = natriuretic peptide receptor | | PKG = protein kinase G |
|
Related Articles
-
A New Role for the Natriuretic Peptides: Metabolic Regulators of the Adipocyte
- Lisa C. Costello-Boerrigter and John C. Burnett, Jr
J. Am. Coll. Cardiol. 2009 53: 2078-2079.
[Full Text]
[PDF]
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A29.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Hozawa, Y. Sugawara, Y. Tomata, M. Kakizaki, T. Tsuboya, K. Ohmori-Matsuda, N. Nakaya, S. Kuriyama, A. Fukao, and I. Tsuji
Relationship Between Serum Adiponectin Levels and Disability-Free Survival Among Community-Dwelling Elderly Individuals: The Tsurugaya Project
J Gerontol A Biol Sci Med Sci,
October 19, 2011;
(2011)
glr191v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Cannone, G. Boerrigter, A. Cataliotti, L. C. Costello-Boerrigter, T. M. Olson, P. M. McKie, D. M. Heublein, B. D. Lahr, K. R. Bailey, M. Averna, et al.
A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community
J. Am. Coll. Cardiol.,
August 2, 2011;
58(6):
629 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clerico, A. Giannoni, S. Vittorini, and C. Passino
Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones
Am J Physiol Heart Circ Physiol,
July 1, 2011;
301(1):
H12 - H20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lorgis, Y. Cottin, N. Danchin, L. Mock, P. Sicard, P. Buffet, I. L'Huillier, C. Richard, J. C. Beer, C. Touzery, et al.
Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction
Heart,
April 1, 2011;
97(7):
551 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Wannamethee, P. Welsh, P. H. Whincup, N. Sawar, M. C. Thomas, V. Gudnarsson, and N. Sattar
High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?
European Journal of Cardiovascular Prevention & Rehabilitation,
February 1, 2011;
18(1):
65 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Watanabe, T. Tamura, K. Ono, H. Horiuchi, T. Kimura, T. Kita, and Y. Furukawa
Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin
Eur J Heart Fail,
November 1, 2010;
12(11):
1214 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Ndisang and A. Jadhav
Heme Arginate Therapy Enhanced Adiponectin and Atrial Natriuretic Peptide, but Abated Endothelin-1 with Attenuation of Kidney Histopathological Lesions in Mineralocorticoid-Induced Hypertension
J. Pharmacol. Exp. Ther.,
July 1, 2010;
334(1):
87 - 98.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gustafsson, L. Lind, B. Zethelius, P. Venge, A. Flyvbjerg, S. Soderberg, and E. Ingelsson
Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies
Eur. J. Endocrinol.,
March 1, 2010;
162(3):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sam and K. Walsh
What can adiponectin say about left ventricular function?
Heart,
March 1, 2010;
96(5):
331 - 332.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Costello-Boerrigter and J. C. Burnett Jr
A New Role for the Natriuretic Peptides: Metabolic Regulators of the Adipocyte
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2078 - 2079.
[Full Text]
[PDF]
|
|
|
|
